# Changes in Glutamatergic Neurotransmission of Severe TBI Patients

> **NCT04244058** · EARLY_PHASE1 · SUSPENDED · sponsor: **Weill Medical College of Cornell University** · enrollment: 30 (estimated)

## Conditions studied

- Disorder of Consciousness
- Traumatic Brain Injury

## Interventions

- **DRUG:** Amantadine + L-DOPA
- **DRUG:** NMDA blocker

## Key facts

- **NCT ID:** NCT04244058
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-09-23
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Given CoVid-19 pandemic we could not recruit subjects/patients for the 1st year. Currently waiting for new sponsor to fulfill the aims.
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04244058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04244058, "Changes in Glutamatergic Neurotransmission of Severe TBI Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04244058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*